Quantcast
Last updated on April 19, 2014 at 9:20 EDT

Latest Oncothyreon Inc. Stories

2012-09-05 02:32:26

SEATTLE, Sept. 5, 2012 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced that an ongoing Phase 2 trial of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer will be expanded to include an additional group of up to 25 patients whose disease has begun to progress while receiving abiraterone (Zytiga®) and prednisone. PX-866 is Oncothyreon's small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K),...

2012-08-29 02:25:28

SEATTLE, Aug. 29, 2012 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) announced today that Robert Kirkman, M.D., President and Chief Executive Officer, will be presenting at the following upcoming investment conferences in September. Stifel Nicolaus 2012 Annual Healthcare Conference Wednesday, September 5, 2012, at 3:15 p.m. Eastern time in Boston, MA Rodman & Renshaw 14(th) Annual Healthcare Conference Tuesday, September 11, 2012, at 10 a.m. Eastern time in New York, NY A...

2012-08-09 06:26:51

Company to Hold Conference Call at 4:30 p.m. EDT Today SEATTLE, Aug. 9, 2012 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) today reported financial results for the second quarter ending June 30, 2012. Loss from operations increased in the second quarter of 2012 to $8.1 million from $5.8 million in the second quarter of 2011, and to $13.8 million for the six months ended June 30, 2012 compared to $11.7 million for the comparable period in 2011. This increase in loss from...

2012-08-08 02:28:16

SEATTLE, WA, Aug. 8, 2012 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced that it will conduct a conference call on Thursday, August 9, 2012 at 4:30 p.m. Eastern Time to discuss its financial results and related matters and provide a review of its pipeline of products in development. To participate in the call by telephone, please dial (877) 280-7291 (United States) or (707) 287-9361 (International).  In addition, the call will be webcast live and can be accessed...

2012-08-08 02:28:16

SEATTLE, WA, Aug. 8, 2012 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) announced today that management will present at the 2012 Wedbush Pacgrow Lifesciences Management Access Conference in New York on Wednesday, August 15, 2012 at 8:35 a.m. Eastern. A live and archived webcast of the presentation will be accessible by visiting the Oncothyreon website www.oncothyreon.com under the "News & Events" section. About Oncothyreon Oncothyreon is a biotechnology company specializing in...

2012-07-24 02:28:34

SEATTLE, July 24, 2012 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced the appointment of Guy F. Cipriani as Vice President, Business Development, effective July 23, 2012.  Mr. Cipriani's will lead Oncothyreon's business development activities for its pipeline of small molecule and immunotherapy product candidates. "Mr. Cipriani is a seasoned executive with more than 12 years of business development experience in the biotechnology and pharmaceutical sectors, and...

2012-06-21 02:26:32

SEATTLE, WA, June 21, 2012 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced the promotion of Scott Peterson, Ph.D., to Chief Scientific Officer.  Dr. Peterson joined Oncothyreon in August 2009 as Vice President, Clinical Development. "This promotion recognizes Scott's key role in advancing the scientific and preclinical support for both PX-866, our phosphatidylinositol-3-kinase (PI-3K) inhibitor currently in multiple Phase 2 clinical trials, and ONT-10, our...

2012-06-02 10:20:13

SEATTLE, June 2, 2012 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced that data from two clinical trials of PX-866, a pan-isoform phosphatidylinositol-3-kinase (PI-3K) inhibitor, were presented today at the American Society of Clinical Oncology (ASCO) meeting in Chicago.  Oncothyreon also provided an update on the status of its ongoing Phase 2 development program for PX-866. Phase 1 Trial of PX-866 in Combination with Docetaxel Data from the Phase 1 portion of...

2012-05-31 10:25:03

SEATTLE, May 31, 2012 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced the initiation of a Phase 1/2 trial of PX-866 in combination with vemurafenib (Zelboraf®).  PX-866 is Oncothyreon's investigational small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K), a component of an important cell survival signaling pathway.  Vemurafenib is a kinase inhibitor indicated for the treatment of unresectable or metastatic...

2012-05-29 02:26:58

SEATTLE, WA, May 29, 2012 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) announced today that Robert Kirkman, M.D., President and Chief Executive Officer, will be presenting at the Jefferies 2012 Global Healthcare Conference in New York on Tuesday, June 5, 2012 at 4:00 p.m. Eastern. A live and archived webcast of the presentation will be accessible by visiting the Oncothyreon website www.oncothyreon.com under the "News & Events" section. About Oncothyreon Oncothyreon is a...